Immunovia discovery study published in top protein research journal
Rhea-AI Summary
Immunovia (IMMNOV) announced the publication of its discovery study in the Journal of Proteome Research, marking it as the largest pancreatic cancer proteomics study to date. The study identified 41 protein biomarkers that strongly correlate with pancreatic ductal adenocarcinoma (PDAC). The research evaluated approximately 3,000 proteins in 329 blood samples from Stage I and II PDAC and non-PDAC matched control patients.
Five of these biomarkers were selected for Immunovia's next-generation test, which demonstrated excellent sensitivity and specificity in detecting early-stage pancreatic cancer. The company plans to launch this test for high-risk individuals in the second half of 2025.
Positive
- Publication in prestigious Journal of Proteome Research validates research quality
- Successfully identified 41 promising protein biomarkers for pancreatic cancer detection
- Next-generation test shows excellent sensitivity and specificity in clinical validation
- Clear commercialization timeline with launch planned for H2 2025
- Large addressable market with 1.8 million high-risk individuals in the USA
Negative
- Commercial revenue from new test not expected until H2 2025
Insights
The publication of Immunovia's discovery study in the Journal of Proteome Research represents a substantial scientific advancement in pancreatic cancer diagnostics. The study's scale - analyzing 3,000 proteins across 329 blood samples - and identification of 41 protein biomarkers specific to early-stage PDAC sets a new benchmark in proteomics research.
The selection of 5 biomarkers for the next-generation test demonstrates a strategic refinement process, optimizing for both sensitivity and specificity in early-stage detection. This is particularly important given that pancreatic cancer is typically diagnosed at late stages when survival rates are extremely poor. The validation of these markers in detecting Stage I and II pancreatic cancer could potentially transform early diagnosis paradigms.
The collaboration with Proteomedix AG and use of Olink multiplex technology adds credibility to the methodology. The planned 2025 commercial launch targeting high-risk individuals, estimated at 1.8 million people in the US alone, indicates significant market potential. However, successful commercialization will depend on clinical adoption, reimbursement policies and competition from other emerging diagnostic technologies.
The discovery study identified 41 promising protein biomarkers that were shown to strongly correlate with the presence of pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer. These protein biomarkers demonstrated the ability to differentiate PDAC cases from non-PDAC controls. About 3,000 proteins were evaluated in 329 blood samples from Stage I and II PDAC and non-PDAC matched control patients using Olink multiplex technology and conventional immunoassays. Results of the discovery study, which was conducted jointly with Immunovia's research partner, Proteomedix AG, were first announced in November 2023.
Five of the 41 biomarkers were selected for inclusion in Immunovia's next-generation test in a subsequent model-development study. The high-performance test was later clinically validated in a study showing excellent sensitivity and specificity in detecting Stage I and II pancreatic cancer, as announced earlier this month.
"This discovery study provided a large number of promising biomarkers from which we built our high-accuracy next-generation test to detect early-stage pancreatic cancer," said Jeff Borcherding, CEO at Immunovia. "Publication of this study in the prestigious Journal of Proteome Research highlights the quality and novelty of our protein discovery program."
Journal of Proteome Research, published by the esteemed American Chemical Society, is recognized as a top-tier journal for research and reports on global protein analysis and function.
Immunovia plans to launch its next-generation test for detection of pancreatic cancer in high-risk individuals in the second half of 2025.
For more information, please contact:
Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com
Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/immunovia-discovery-study-published-in-top-protein-research-journal-302337208.html
SOURCE Immunovia AB
FAQ
What are the key findings of Immunovia's (IMMNOV) pancreatic cancer discovery study?
When will Immunovia (IMMNOV) launch its next-generation pancreatic cancer test?
How many proteins did Immunovia's (IMMNOV) study evaluate?
What is the market size for Immunovia's (IMMNOV) pancreatic cancer test in the USA?
Which research partner collaborated with Immunovia (IMMNOV) on the discovery study?
